<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987593</url>
  </required_header>
  <id_info>
    <org_study_id>HND-IN-039</org_study_id>
    <nct_id>NCT04987593</nct_id>
  </id_info>
  <brief_title>Characterisation of the Gut Microbiota in Term Infants After Maternal Supplementation of Probiotics</brief_title>
  <official_title>Characterisation of the Gut Microbiota in Term Infants After Maternal Prenatal and Postnatal Supplementation of Probiotics - an Open Label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chr Hansen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A monocenter, open label pilot study in pregnant women and their offspring with at least four&#xD;
      weeks prenatal and four weeks postnatal maternal intervention with a study product consisting&#xD;
      of four different food constituents.&#xD;
&#xD;
      The study will investigate the effect of maternal supplementation with the food constituents&#xD;
      on the recovery of the constituents in the maternal and infant feces, the microbiota in both&#xD;
      mother and infant and potential transmission routes from mother to infant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women will be recruited at the ordinary midwife visit in gestational week 28. The&#xD;
      intervention will begin in gestational week 33+0 to ensure at least four weeks prenatal&#xD;
      intervention before expected birth.&#xD;
&#xD;
      The study will be conducted in four phases. First phase is the run-in phase. The second phase&#xD;
      is the prenatal intervention period from gestational week 33+0 until birth. Third phase is&#xD;
      the postnatal intervention period, from birth until four weeks postnatal. The last phase is a&#xD;
      two weeks follow-up period without any intake of the investigational product.&#xD;
&#xD;
      Infant stool samples, as well as maternal breast milk samples, stool and urine samples and&#xD;
      samples from vagina will be collected on multiple occasions during the study. In addition,&#xD;
      sample from placenta, umbilical cord, umbilical cord blood and amnion fluid will be&#xD;
      collected. Mothers will be asked to complete electronic questionnaires daily during the&#xD;
      course of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of study product in infant feces</measure>
    <time_frame>28 days after birth</time_frame>
    <description>Presence of at least one of the probiotic strains in infant feces using PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of study product in maternal feces</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of at least one of the probiotic strains in maternal feces using PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the microbiota in breastmilk</measure>
    <time_frame>28 days after birth</time_frame>
    <description>Characterization of breastmilk microbiota by and recovery of probiotic strains using PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the maternal vaginal microbiota</measure>
    <time_frame>28 days</time_frame>
    <description>Characterization of the vaginal microbiota and recovery of probiotic strains using PCR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Infant gastrointestinal problems</measure>
    <time_frame>28 days</time_frame>
    <description>Infants gastrointestinal problems will be assessed using the Parent-Report Form for Neonates Section A - Infant Gastrointestinal Problems (ROME IV)</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant stool frequency and consistency</measure>
    <time_frame>28 days</time_frame>
    <description>Infants stool frequency and consistency will be assessed using Amsterdam Stool Chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant Reflux</measure>
    <time_frame>28 days</time_frame>
    <description>Reflux will be assessed using the Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Any adverse events experienced by either mother or infant will be recorded during the entire study period</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Infant Development</condition>
  <condition>Gut Microbiome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four probiotic strains to be consumed once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Pregnant women:&#xD;
&#xD;
          1. Enrolled at Aarhus University Hospital&#xD;
&#xD;
          2. Singleton pregnancy&#xD;
&#xD;
          3. Age above 18 years at informed consent&#xD;
&#xD;
          4. Aim to give birth vaginally&#xD;
&#xD;
          5. Aim to breastfeed&#xD;
&#xD;
          6. No use of probiotics (contained in dietary supplements/ food) after written consent.&#xD;
&#xD;
        Infants:&#xD;
&#xD;
        1. Gestational age between 37-42 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant women • Use of immunosuppressant drugs.&#xD;
&#xD;
        Infants:&#xD;
&#xD;
        • None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Henning Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Høtoft, Midwife</last_name>
    <phone>+45 23486730</phone>
    <email>diahoe@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gynaecology and Obstetrics</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Høtoft, Midwife</last_name>
    </contact>
    <investigator>
      <last_name>Diana Høtoft, Midwife</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Henning Pedersen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD plan yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

